Editas Medicine(US:EDIT) Globenewswire·2025-11-10 12:00Core Insights - Editas Medicine has presented preclinical proof-of-concept data showing over 90% reduction in LDL cholesterol levels in non-human primates, supporting the potential of EDIT-401 as a leading one-time therapy [1][2] - The company is on track to submit an investigational new drug (IND) or clinical trial application (CTA) for EDIT-401 by mid-2026, with initial human proof-of-concept data expected by the end of 2026 [1][2] - Editas has extended its cash runway into the third quarter of 2027, allowing for further development of EDIT-401 beyond initial human proof-of-concept data [1][4] Recent Achievements and Outlook - The company has made significant progress with EDIT-401, achieving over 90% LDL cholesterol reduction in non-human primates within 48 hours of a single dose [5] - A ≥6-fold mean increase in LDLR protein in the liver of non-human primates was observed, requiring only moderate functional editing of LDLR alleles (approximately 10-40%) [5] - The durability of LDL-C reduction was demonstrated in mouse models over a three-month study [5] Financial Results - As of September 30, 2025, cash, cash equivalents, and marketable securities totaled $165.6 million, down from $269.9 million as of December 31, 2024 [7][15] - The company raised $17.8 million in gross equity proceeds from its at-the-market (ATM) facility during the third quarter of 2025 [7] - For the three months ended September 30, 2025, the net loss attributable to common stockholders was $25.1 million, or $0.28 per share, compared to a net loss of $62.1 million, or $0.75 per share, for the same period in 2024 [11][14] Corporate Highlights - Editas has maintained financial discipline, which contributed to extending its cash runway into the third quarter of 2027 [4] - The company plans to participate in the 8th Annual Evercore Healthcare Conference on December 2, 2025 [5]